Chinese biotech deals soar to record $60 billion in Q1 2026
Chinese biotech companies recorded a staggering $60 billion in cross-border licensing deals in the first quarter of 2026, reflecting a growing interest from multinational corporations in promising drug candidates from China. This marks a significant increase of 73% compared to the same period last year.